In Vivo Imaging as a Pharmacodynamic Marker

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-13-2666
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy

JAMA Neurology
Neurology
2013English

Figure 1: ATF4 as a Pharmacodynamic Marker in Nontransgenic and hAPP-J20 Mice.

English

Imaging the Pathoanatomy of Amyotrophic Lateral Sclerosis in Vivo: Targeting a Propagation-Based Biological Marker

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2017English

SYTO-13, a Viability Marker as a New Tool to Monitor in Vitro Pharmacodynamic Parameters of Anti-Pneumocystis Drugs

PLoS ONE
Multidisciplinary
2015English

PfCap380 as a Marker for Plasmodium Falciparum Oocyst Development in Vivo and in Vitro

Malaria Journal
ParasitologyInfectious Diseases
2018English

In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2007English

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2017English

In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2007English

Mass-Forming Intrahepatic Cholangiocarcinoma: Diffusion-Weighted Imaging as a Preoperative Prognostic Marker

Radiology
Nuclear MedicineRadiologyImaging
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy